Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life

OBJECTIVE: The aim of this study was to determine if direct-acting antiviral (DAA) treatment with daclatasvir (DCV) plus asunaprevir (ASV) for 24 weeks influenced the health-related quality of life (HRQOL) at 12 and 24 weeks after treatment initiation [end of treatment (EOT)]. METHODS: This was a pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Intern Med
Main Authors: Kawakubo, Megumi, Eguchi, Yuichiro, Okada, Michiaki, Iwane, Shinji, Oeda, Satoshi, Otsuka, Taiga, Nakashita, Syunya, Araki, Norimasa, Koga, Akemi
Formato: Artigo
Idioma:Inglês
Publicado em: The Japanese Society of Internal Medicine 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6096027/
https://ncbi.nlm.nih.gov/pubmed/29526929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0091-17
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados